Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Understanding & Predicting Brain Penetration for CNS-targeted Drugs

There are numerous strategies available incorporating in silico, in vitro and in vivo tools for optimising brain exposure for CNS-target drugs.

What do you think are the pros and cons of each strategy? At the Romark Medicinal Chemistry Symposium that was held recently in Liverpool, our Director of DMPK, Tim Schulz-Utermoehl, provided an overview of this area.

Check out the slides following the link below:

Romark Medicinal Chemistry Syposium 2018 Slideset

Why don’t you let us know your thoughts!

Latest News

View All

Sygnature Discovery and UBE Corporation successfully identify…

Sygnature Discovery’s hit finding expertise in high…

Sygnature Discovery accelerates global growth with major…

Sygnature Discovery launches its in vivo LPS…